Figures & data
Figure 1 Schematic illustration of in vivo-induced MR imaging of a tumor employing SHP2-targeted nanoparticles.
![Figure 1 Schematic illustration of in vivo-induced MR imaging of a tumor employing SHP2-targeted nanoparticles.](/cms/asset/3fe29d35-b154-4a01-bc78-094da3524216/dijn_a_12190864_f0001_c.jpg)
Figure 2 Characterization of the SHP2-targeted nanoparticles. (A) Brightfield optical microscopy image, (B) size distribution and (C) zeta potential.
![Figure 2 Characterization of the SHP2-targeted nanoparticles. (A) Brightfield optical microscopy image, (B) size distribution and (C) zeta potential.](/cms/asset/09aa6580-ff8a-48b5-883b-7563c98b7c48/dijn_a_12190864_f0002_c.jpg)
Figure 3 In vitro cytotoxicity experiments. (A) The proliferative effects of SHP2-targeted nanoparticles on Nthori3-1 cells. (B and C) After treatment with NPs in SW579 cells, SHP2-NPs and DOX, BAX and caspase-3 expression were significantly increased, while bcl-2 expression was decreased compared with any other group (**P<0.01, *P<0.05).
![Figure 3 In vitro cytotoxicity experiments. (A) The proliferative effects of SHP2-targeted nanoparticles on Nthori3-1 cells. (B and C) After treatment with NPs in SW579 cells, SHP2-NPs and DOX, BAX and caspase-3 expression were significantly increased, while bcl-2 expression was decreased compared with any other group (**P<0.01, *P<0.05).](/cms/asset/5b5ca737-f632-4f59-ae86-79498a105c08/dijn_a_12190864_f0003_b.jpg)
Figure 4 (A) T1-weighted images of nanoparticles with different Gd3+ concentrations and (B) the corresponding SNR (the Gd3+ concentration of nanoparticles was 1: 3.000, 2: 2.000, 3: 1.000, 4: 0.5000 and 5: 0.2500 mmol /L; and 6: 1% agarose gel solution (*P<0.05).
![Figure 4 (A) T1-weighted images of nanoparticles with different Gd3+ concentrations and (B) the corresponding SNR (the Gd3+ concentration of nanoparticles was 1: 3.000, 2: 2.000, 3: 1.000, 4: 0.5000 and 5: 0.2500 mmol /L; and 6: 1% agarose gel solution (*P<0.05).](/cms/asset/054b9727-6d25-4b89-b58b-456221502c9a/dijn_a_12190864_f0004_b.jpg)
Figure 5 In vitro targeting ability experiments. (A) Fluorescence images showing the results of binding with SW579 cells for SHP2-targeted and nontargeted nanoparticles. (B) After SHP2-targeted nanoparticle treatment, the red fluorescence signal around the cells increased significantly compared with that obtained after treatment the nontargeted nanoparticles (control) (**P<0.01).
![Figure 5 In vitro targeting ability experiments. (A) Fluorescence images showing the results of binding with SW579 cells for SHP2-targeted and nontargeted nanoparticles. (B) After SHP2-targeted nanoparticle treatment, the red fluorescence signal around the cells increased significantly compared with that obtained after treatment the nontargeted nanoparticles (control) (**P<0.01).](/cms/asset/e25a1487-1706-4b07-9922-a5a4e2b4353a/dijn_a_12190864_f0005_c.jpg)
Figure 6 (A) Subcutaneous human thyroid carcinoma xenograft tumor (blue dashed line) imaged with contrast-enhanced MR after the injection of SHP2-targeted and nontargeted nanoparticles and LIFU irradiation for 5 mins. (B) The imaging signal obtained after SHP2-targeted nanoparticle injection was substantially higher than that obtained after nontargeted nanoparticle (control) injection (*P<0.05).
![Figure 6 (A) Subcutaneous human thyroid carcinoma xenograft tumor (blue dashed line) imaged with contrast-enhanced MR after the injection of SHP2-targeted and nontargeted nanoparticles and LIFU irradiation for 5 mins. (B) The imaging signal obtained after SHP2-targeted nanoparticle injection was substantially higher than that obtained after nontargeted nanoparticle (control) injection (*P<0.05).](/cms/asset/261744a3-f747-4aa3-aec1-569a34a499c7/dijn_a_12190864_f0006_c.jpg)